Patient first… patient centric… patient focused… Do these terms sound familiar? These phrases have become a regular feature in clinical research language. They appear in brochures, mission statements, and recruitment materials. They signal a commitment to prioritizing patient needs and well-being.
These terms are used with good intentions, but has common usage made them a superficial label? Do they truly reflect the deep commitment that they signify? Many patients perceive these terms as hollow and meaningless. Being put “first” translates to signing forms and sitting in waiting rooms, not shaping the study, not being truly heard.
Putting patients first must be more than a slogan. It needs to be a standard of care, respect, and collaboration. If clinical research is to evolve into something genuinely equitable, it has to center patients not just in process, but in power. That means co-creation, transparency, and accountability, well beyond what’s captured in a consent form.
Patient-first approaches have to go beyond the paperwork. Putting patients first must fundamentally mean more than securing informed consent. Consent is a crucial ethical minimum, not the pinnacle of patient partnership. This change begins with treating patients not as passive recipients of care, but as drivers of research decisions, and it continues with every decision that prioritizes their experience, feedback, and well-being.
The Gap: When Rhetoric Outpaces Reality
“Patient first” is a great motto, but it runs the risk of becoming corporate jargon or a marketing claim that has no substantive changes in practice.
Consent is not a substantive change. You may have taken part in a trial that was designed with the notion that the informed consent process alone fulfills the “patient first” promise, and felt like you really weren’t a priority for the rest of the trial. While informed consent is essential for autonomy and clinical trial ethics, it doesn’t automatically guarantee that the patient’s experience, input, or broader needs are prioritized throughout the trial.
Sponsors must also avoid superficial gestures. Some examples are advisory panels without real influence, feedback surveys that go into a void, or patient materials developed without patient input. These illusions of partnership undermine trust rather than build it.
Defining Authentic “Patient First” Principles
Change begins with deep respect for patients as partners. It’s going beyond politeness to genuinely valuing patients’ lived experience as expertise. It’s respecting their time through efficient visits and fair compensation and respecting their dignity and choices. It’s shifting from viewing participants as “subjects” to seeing them as active collaborators in the research process.
The next step is meaningful inclusion and co-design. This step involves patients early and continuously in trial design not just in reviewing finished documents. It means seeking input on things like research questions, protocol feasibility, endpoint selection, site selection, and communication strategies. It ensures patient-facing materials are truly understandable, accessible, and co-created with patients.
Transparency is what holds everything together. Patients need clear, honest, ongoing communication about the trial’s purpose, procedures, risks, potential benefits, and progress. They rely on a commitment to sharing both positive and negative trial results with them and the whole patient community in plain language. Patients appreciate openness about how their data will be used.
A well-rounded patient support system isn’t complete without empathy. Sponsors must actively work to reduce the burden of participation through travel support, flexible scheduling, and user-friendly technology. They need to understand the wider needs of participants beyond the specific trial procedures and provide clear channels for questions and concerns.
Voices Calling for Substance
Discussions within the community, for instance on professional platforms like LinkedIn, often highlight the difference between trials that merely claim to be “patient-first” and those that demonstrate it through tangible actions like co-design or truly responsive communication. These conversations underscore the demand for authenticity in clinical trial ethics. The following LinkedIn post is just one example of this invaluable resource.
Patient First? What That Really Means… Saying “patient-first” doesn’t make it true. It’s easy to put “patients at the center” in a mission statement. It’s harder to design trials that actually work for them. Being patient-first means more than offering a consent form and a thank-you gift. It means designing trials that fit around real lives, not the other way around. It means respecting time, effort, and emotional load. It means offering clarity at every stage, not just at the start.
If a trial requires multiple long-distance site visits, is it patient-first? If participation creates financial strain, is it patient-first? If communication is confusing, inconsistent, or absent, is it patient-first? Here’s a better test: Would I want my partner, parent, or child in this trial? If the answer is “not really,” it’s not patient-first.
Why Real “Patient First” Matters: The Impact
A real “patient first” mindset reaches far beyond one specific trial. It builds foundational trust. Authentic respect and inclusion are cornerstones of trust between patients and the research enterprise.
It improves trial quality and relevance. Patient input leads to better-designed trials that are more feasible, easier to join, keep participants longer, and measure outcomes that are truly meaningful. People who understand what they are agreeing to before they enroll are far less likely to leave once they are in.
It accelerates progress. Participants who understand the study and trust the team join sooner and stay to the end, which speeds up the completion of trials and the development of effective treatments.
It’s ethically imperative. Fundamentally, treating participants with respect and valuing their contribution is simply the right thing to do. Real change means giving patients the power to lead, not just respond. It means embedding them into the DNA of the research process, from strategy to results. That’s what makes the difference between inclusion and empowerment. If you are designing a study and want people to understand it before they are asked to decide, see what trialport does for sponsors and CROs.
About the author
Keith Berelowitz has spent more than twenty years watching clinical trials work on paper and struggle in real life. He has helped run studies, advises sponsors and CROs on how they engage with people, and chairs a UK research ethics committee, where consent forms and participant information sheets cross his desk every month. That vantage point led to one conclusion: most trial problems are not failures of science. They are failures of understanding at the moment a person decides.
He founded trialport, a clinical trial navigation and decision-support platform, on a principle he brings from the ethics committee: clarity is an ethical issue, not only a communication one. People should understand what they are being asked to consider before they are asked to decide. Understanding comes first. Decisions follow.